Nasopharyngeal cancer

Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol. 2021 Mar 1;39(7):840-59.Full text  Abstract

Bossi P, Chan AT, Licitra L, et al. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Apr;32(4):452-65.Full text  Abstract

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers​ [internet publication].Full text

Maghami E, Ismaila N, Alvarez A, et al. Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck: ASCO guideline. J Clin Oncol. 2020 Aug 1;38(22):2570-96.Full text  Abstract

Lee AWM, Lee VHF, Ng WT, et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer. 2021 Aug;153:109-22. Abstract

1. Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol. 2021 Mar 1;39(7):840-59.Full text  Abstract

2. Bossi P, Chan AT, Licitra L, et al. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Apr;32(4):452-65.Full text  Abstract

3. El-Naggar AK, Chan JK, Grandis JR, et al. WHO classification of head and neck tumours: WHO classification of tumours. 4th ed, vol 9. Lyon: IARC Publications; 2017​.

4. Lee AW, Foo W, Law SC, et al. Nasopharyngeal carcinoma: presenting symptoms and duration before diagnosis. Hong Kong Med J. 1997 Dec;3(4):355-61.Full text  Abstract

5. Ho FC, Tham IW, Earnest A, et al. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence. BMC Cancer. 2012 Mar 21;12:98.Full text  Abstract

6. Ludwig R, Hoffmann JM, Pouymayou B, et al. Detailed patient-individual reporting of lymph node involvement in oropharyngeal squamous cell carcinoma with an online interface. Radiother Oncol. 2022 Apr;169:1-7.Full text  Abstract

7. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49.Full text  Abstract

8. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48.Full text  Abstract

9. Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma. Lancet. 2019 Jul;394(10192):64-80. Abstract

10. Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000 Dec;60(24):6878-81. Abstract

11. Tsao SW, Yip YL, Tsang CM, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014 May;50(5):330-8.Full text  Abstract

12. Loh KS, Goh BC, Lu J, et al. Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):82-5.Full text  Abstract

13. Xue WQ, Qin HD, Ruan HL, et al. Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of studies conducted between 1979 and 2011. Am J Epidemiol. 2013 Aug;178(3):325-38.Full text  Abstract

14. Long M, Fu Z, Li P, et al. Cigarette smoking and the risk of nasopharyngeal carcinoma: a meta-analysis of epidemiological studies. BMJ Open. 2017 Oct;7(10):e016582.Full text  Abstract

15. Yu MC, Ho JH, Lai SH, et al. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. Cancer Res. 1986 Feb;46(2):956-61. Abstract

16. Lanier A, Bender T, Talbot M, et al. Nasopharyngeal carcinoma in Alaskan Eskimos Indians, and Aleuts: a review of cases and study of Epstein-Barr virus, HLA, and environmental risk factors. Cancer. 1980 Nov;46(9):2100-6. Abstract

17. Huang WB, Chan JYW, Liu DL. Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: multicenter study from an endemic area in Southern China. Cancer. 2018 Feb 1;124(3):530-6.Full text  Abstract

18. Chan AT, Teo PM, Leung TW, et al. The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer. 1998 Mar 15;82(6):1003-12. Abstract

19. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck cancers​ [internet publication].Full text

20. Pynnonen MA, Gillespie MB, Roman B, et al. Clinical practice guideline: evaluation of the neck mass in adults. Otolaryngol Head Neck Surg. 2017 Sep;157(2 suppl):S1-30.Full text  Abstract

21. Expert Panel on Neurologic Imaging; Aulino JM, Kirsch CFE, et al. ACR appropriateness criteria(®) neck mass-adenopathy. J Am Coll Radiol. 2019 May;16(5s):S150-60.Full text  Abstract

22. Maghami E, Ismaila N, Alvarez A, et al. Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck: ASCO guideline. J Clin Oncol. 2020 Aug 1;38(22):2570-96.Full text  Abstract

23. Lee AWM, Lee VHF, Ng WT, et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer. 2021 Aug;153:109-22. Abstract

24. Liu L, Liang S, Li L, et al. Prognostic impact of magnetic resonance imaging-detected cranial nerve involvement in nasopharyngeal carcinoma. Cancer. 2009 May 1;115(9):1995-2003.Full text  Abstract

25. Guo R, Mao YP, Tang LL, et al. The evolution of nasopharyngeal carcinoma staging. Br J Radiol. 2019 Oct;92(1102):20190244.Full text  Abstract

26. Tang LQ, Chen QY, Fan W, et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2013 Aug 10;31(23):2861-9.Full text  Abstract

27. Guo R, Tang LL, Mao YP, et al. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer. 2019 Jan 1;125(1):79-89.Full text  Abstract

28. Amin MB, Edge S, Greene F, et al. AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.

29. Allen PB, Lechowicz MJ. Management of NK/T-cell lymphoma, nasal type. J Oncol Pract. 2019 Oct;15(10):513-20.Full text  Abstract

30. Tang LL, Huang CL, Zhang N, et al. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022 Apr;23(4):479-90. Abstract

31. Pan JJ, Ng WT, Zong JF, et al. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016 Feb 15;122(4):546-58.Full text  Abstract

32. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006 Dec 1;24(34):5414-8.Full text  Abstract

33. Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016 Oct 15;388(10054):1883-92. Abstract

34. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-35.Full text  Abstract

35. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998 Apr;16(4):1310-7.Full text  Abstract

36. Ng WT, Soong YL, Ahn YC, et al. International recommendations on reirradiation by intensity modulated radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):682-95. Abstract

37. Mai HQ, Chen QY, Chen D, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA. 2023 Nov 28;330(20):1961-70.Full text  Abstract

38. Bossi P, Chan AT, Even C, et al. ESMO-EURACAN clinical practice guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent/metastatic disease. Ann Oncol. 2023 Mar;34(3):247-50.Full text  Abstract

39. Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021 Aug;22(8):1162-74. Abstract

40. ClinicalTrials.gov. Phase III study of camrelizumab in combination with chemotherapy in recurrent/​metastatic nasopharyngeal carcinoma. ClinicalTrials.gov Identifier: NCT03707509. Jul 2022 [internet publication].Full text

41. Miao J, Wang L, Tan SH, et al. Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial. JAMA Oncol. 2022 Oct 13;8(12):1776-85.Full text  Abstract

42. ClinicalTrials.gov. Nanatinostat plus valganciclovir in patients with advanced EBV+ solid tumors, and in combination with pembrolizumab in EBV+ RM-NPC. ClinicalTrials.gov Identifier: NCT05166577. Mar 2024 [internet publication].Full text

43. Ma SX, Zhou T, Huang Y, et al. The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Ann Transl Med. 2018 Jun;6(11):201.Full text  Abstract

44. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005 Jun 11-17;365(9476):2041-54. Abstract